Trial Profile

An Observer-Blinded, Randomized Study Comparing the Safety and Immunogenicity of HEPLISAV-B to Licensed Vaccine (Engerix-B) Among Adults(18 to 75 Years of Age) With Chronic Kidney Disease (CKD)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adjuvanted Hepatitis-B vaccine (Recombinant)-Dynavax (Primary) ; Alum; Hepatitis B vaccine recombinant
Indications Hepatitis B
Focus Pharmacodynamics; Registrational
Sponsors Dynavax Technologies

Most Recent Events

24 Sep 2013 Results have been published in Vaccine according to a Dynavax Technologies Corporation media release.
27 Mar 2012 Primary endpoint 'Antibody-levels' has been met.
27 Mar 2012 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com